Literature DB >> 24755332

"Triplet" polycistronic vectors encoding Gata4, Mef2c, and Tbx5 enhances postinfarct ventricular functional improvement compared with singlet vectors.

Megumi Mathison1, Vivek P Singh1, Robert P Gersch2, Maricela O Ramirez1, Austin Cooney1, Stephen M Kaminsky3, Maria J Chiuchiolo3, Ahmed Nasser2, Jianchang Yang4, Ronald G Crystal3, Todd K Rosengart5.   

Abstract

OBJECTIVE: The in situ reprogramming of cardiac fibroblasts into induced cardiomyocytes by the administration of gene transfer vectors encoding Gata4 (G), Mef2c (M), and Tbx5 (T) has been shown to improve ventricular function in myocardial infarction models. The efficacy of this strategy could, however, be limited by the need for fibroblast targets to be infected 3 times--once by each of the 3 transgene vectors. We hypothesized that a polycistronic "triplet" vector encoding all 3 transgenes would enhance postinfarct ventricular function compared with use of "singlet" vectors.
METHODS: After validation of the polycistronic vector expression in vitro, adult male Fischer 344 rats (n=6) underwent coronary ligation with or without intramyocardial administration of an adenovirus encoding all 3 major vascular endothelial growth factor (VEGF) isoforms (AdVEGF-All6A positive), followed 3 weeks later by the administration to AdVEGF-All6A-positive treated rats of singlet lentivirus encoding G, M, or T (1×10(5) transducing units each) or the same total dose of a GMT "triplet" lentivirus vector.
RESULTS: Western blots demonstrated that triplet and singlet vectors yielded equivalent GMT transgene expression, and fluorescence activated cell sorting demonstrated that triplet vectors were nearly twice as potent as singlet vectors in generating induced cardiomyocytes from cardiac fibroblasts. Echocardiography demonstrated that GMT triplet vectors were more effective than the 3 combined singlet vectors in enhancing ventricular function from postinfarct baselines (triplet, 37%±10%; singlet, 13%±7%; negative control, 9%±5%; P<.05).
CONCLUSIONS: These data have confirmed that the in situ administration of G, M, and T induces postinfarct ventricular functional improvement and that GMT polycistronic vectors enhance the efficacy of this strategy.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24755332     DOI: 10.1016/j.jtcvs.2014.03.033

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  30 in total

1.  Cardiac reprogramming factor Gata4 reduces postinfarct cardiac fibrosis through direct repression of the profibrotic mediator snail.

Authors:  Megumi Mathison; Vivek P Singh; Deepthi Sanagasetti; Lina Yang; Jaya Pratap Pinnamaneni; Jianchang Yang; Todd K Rosengart
Journal:  J Thorac Cardiovasc Surg       Date:  2017-06-21       Impact factor: 5.209

2.  In situ reprogramming to transdifferentiate fibroblasts into cardiomyocytes using adenoviral vectors: Implications for clinical myocardial regeneration.

Authors:  Megumi Mathison; Vivek P Singh; Maria J Chiuchiolo; Deepthi Sanagasetti; Yun Mao; Vivekkumar B Patel; Jianchang Yang; Stephen M Kaminsky; Ronald G Crystal; Todd K Rosengart
Journal:  J Thorac Cardiovasc Surg       Date:  2016-09-23       Impact factor: 5.209

Review 3.  Transcriptional control of cardiac fibroblast plasticity.

Authors:  Janet K Lighthouse; Eric M Small
Journal:  J Mol Cell Cardiol       Date:  2015-12-22       Impact factor: 5.000

4.  Initiating Events in Direct Cardiomyocyte Reprogramming.

Authors:  Kimberly Sauls; Todd M Greco; Li Wang; Meng Zou; Michelle Villasmil; Li Qian; Ileana M Cristea; Frank L Conlon
Journal:  Cell Rep       Date:  2018-02-13       Impact factor: 9.423

Review 5.  Direct Cardiac Cellular Reprogramming for Cardiac Regeneration.

Authors:  Vivekkumar Patel; Megumi Mathison; Vivek P Singh; Jianchang Yang; Todd K Rosengart
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-09

Review 6.  Internal ribosome entry site-based vectors for combined gene therapy.

Authors:  Edith Renaud-Gabardos; Fransky Hantelys; Florent Morfoisse; Xavier Chaufour; Barbara Garmy-Susini; Anne-Catherine Prats
Journal:  World J Exp Med       Date:  2015-02-20

7.  Cardiac stem cell trials and the new world of cellular reprogramming: Time to move on.

Authors:  Todd K Rosengart; Vivek Patel; Frank W Sellke
Journal:  J Thorac Cardiovasc Surg       Date:  2017-12-26       Impact factor: 5.209

Review 8.  Molecular discoveries and treatment strategies by direct reprogramming in cardiac regeneration.

Authors:  John H Werner; John H Rosenberg; John Y Um; Michael J Moulton; Devendra K Agrawal
Journal:  Transl Res       Date:  2018-07-31       Impact factor: 7.012

9.  Therapeutic Benefit and Gene Network Regulation by Combined Gene Transfer of Apelin, FGF2, and SERCA2a into Ischemic Heart.

Authors:  Edith Renaud-Gabardos; Florence Tatin; Fransky Hantelys; Benoît Lebas; Denis Calise; Oksana Kunduzova; Bernard Masri; Françoise Pujol; Pierre Sicard; Philippe Valet; Jérôme Roncalli; Xavier Chaufour; Barbara Garmy-Susini; Angelo Parini; Anne-Catherine Prats
Journal:  Mol Ther       Date:  2017-11-16       Impact factor: 11.454

10.  p63 Silencing induces reprogramming of cardiac fibroblasts into cardiomyocyte-like cells.

Authors:  Vivekkumar Patel; Vivek P Singh; Jaya Pratap Pinnamaneni; Deepthi Sanagasetti; Jacqueline Olive; Megumi Mathison; Austin Cooney; Elsa R Flores; Ronald G Crystal; Jianchang Yang; Todd K Rosengart
Journal:  J Thorac Cardiovasc Surg       Date:  2018-04-13       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.